|
DE69825066T2
(de)
*
|
1997-02-07 |
2005-08-25 |
Princeton University |
Gentechnisch hergestellte Proteinkinasen, welche modifizierte Nukleotidtriphosphatsubstrate verwenden können
|
|
US6162613A
(en)
*
|
1998-02-18 |
2000-12-19 |
Vertex Pharmaceuticals, Inc. |
Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
|
|
US7383135B1
(en)
|
1998-05-04 |
2008-06-03 |
Vertex Pharmaceuticals Incorporated |
Methods of designing inhibitors for JNK kinases
|
|
US6610483B1
(en)
*
|
1999-07-23 |
2003-08-26 |
Princeton University |
Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof
|
|
DE10024174A1
(de)
*
|
2000-05-17 |
2001-11-29 |
Gsf Forschungszentrum Umwelt |
Verfahren zum Selektieren von Inhibitoren für Enzyme
|
|
US7792645B2
(en)
*
|
2000-08-30 |
2010-09-07 |
The Salk Institute For Biological Studies |
Three-dimensional structure of chalcone isomerase and methods of use thereof
|
|
WO2002057418A2
(en)
*
|
2000-12-15 |
2002-07-25 |
The Salk Institute For Biological Studies |
Methods of producing polyketide synthase mutants and compositions and uses thereof
|
|
MXPA03009957A
(es)
|
2001-04-30 |
2005-07-25 |
Vertex Pharma |
Inhibidores de la gsk-3 y estructuras cristalinas de la proteina gsk-3¦ y complejos de proteina.
|
|
US20060263800A1
(en)
*
|
2001-11-01 |
2006-11-23 |
Princeton University |
Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
|
|
WO2003105723A2
(en)
*
|
2002-06-14 |
2003-12-24 |
The Salk Institute For Biological Studies |
Mutant plant caffeic acid/5-hydroxyferulic acid 3/5-0-methyltransferases (comt), methods for preparation and use thereof
|
|
US20040241706A1
(en)
*
|
2002-09-13 |
2004-12-02 |
Irm, Llc |
Highly specific modulators of GTPases for target validation
|
|
TW200418498A
(en)
*
|
2002-09-30 |
2004-10-01 |
Genelabs Tech Inc |
Nucleoside derivatives for treating hepatitis C virus infection
|
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
|
EP1656379B1
(en)
*
|
2003-08-15 |
2007-01-10 |
Merck & Co., Inc. |
4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists
|
|
WO2006045512A1
(en)
*
|
2004-10-19 |
2006-05-04 |
Krka, Tovarna Zdravil |
Solid pharmaceutical composition comprising donepezil hydrochloride
|
|
WO2006068760A2
(en)
*
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Anti-inflammatory pyrazolopyrimidines
|
|
WO2007044932A2
(en)
*
|
2005-10-13 |
2007-04-19 |
Activesite Pharmaceuticals |
Methods for indentification of inhibitors of enzyme activity
|
|
GB2453058A
(en)
*
|
2006-04-04 |
2009-03-25 |
Univ California |
Kinase antagonists
|
|
WO2008095140A1
(en)
*
|
2007-01-31 |
2008-08-07 |
Bids Trading, L.P. |
Electronic block trading system and method of operation
|
|
WO2009046448A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
CN104926815B
(zh)
|
2008-01-04 |
2017-11-03 |
英特利凯恩有限责任公司 |
某些化学实体、组合物和方法
|
|
US8065217B2
(en)
*
|
2008-02-12 |
2011-11-22 |
Bids Trading, L.P. |
Real-time portfolio balancing and/or optimization system and method
|
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン， エルエルシー |
キナーゼ阻害剤および使用方法
|
|
WO2010006086A2
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
|
EP2346508B1
(en)
|
2008-09-26 |
2016-08-24 |
Intellikine, LLC |
Heterocyclic kinase inhibitors
|
|
JP5819195B2
(ja)
|
2008-10-16 |
2015-11-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
融合環ヘテロアリールキナーゼ阻害剤
|
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
|
WO2011146882A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2013012915A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
CN103998442B
(zh)
|
2011-08-29 |
2016-09-14 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
EP2751112B1
(en)
|
2011-09-02 |
2019-10-09 |
The Regents of The University of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
KR20150061651A
(ko)
|
2012-09-26 |
2015-06-04 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ire1의 조절
|
|
HRP20181367T4
(hr)
|
2012-11-01 |
2021-11-26 |
Infinity Pharmaceuticals, Inc. |
Liječenje raka korištenjem modulatora izoforme pi3 kinaze
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
EP2976086B1
(en)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
|
US10769725B1
(en)
|
2013-06-05 |
2020-09-08 |
Bids Trading, L.P. |
System and methods for optimizing the effectiveness of interaction between participants in an electronic trading environment
|
|
MX389256B
(es)
|
2013-10-04 |
2025-03-20 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN113616656B
(zh)
|
2014-03-19 |
2023-02-17 |
无限药品股份有限公司 |
用于治疗PI3K-γ介导的障碍的杂环化合物
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
EP3801069A4
(en)
|
2018-06-01 |
2022-03-16 |
Cornell University |
MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
|
|
JP2023508978A
(ja)
*
|
2019-12-23 |
2023-03-06 |
サンフォード バーナム プレビス メディカル ディスカバリー インスティテュート |
エクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ１（ｅｎｐｐ１）モジュレーター及びその使用
|
|
US12215108B2
(en)
|
2022-01-10 |
2025-02-04 |
Southern Research Institute |
Development of potential antidotes for arsenicals
|